• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

PD-L1 表达与 HPV 阴性头颈部鳞状细胞癌患者的肿瘤浸润淋巴细胞及预后相关。

PD-L1 expression correlates with tumor-infiltrating lymphocytes and better prognosis in patients with HPV-negative head and neck squamous cell carcinomas.

机构信息

Department of Otolaryngology, Hospital Universitario Central de Asturias and Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Instituto Universitario de Oncología del Principado de Asturias, University of Oviedo, 33011, Oviedo, Spain.

Ciber de Cáncer, CIBERONC, 28029, Madrid, Spain.

出版信息

Cancer Immunol Immunother. 2020 Oct;69(10):2089-2100. doi: 10.1007/s00262-020-02604-w. Epub 2020 May 24.

DOI:10.1007/s00262-020-02604-w
PMID:32448984
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11027666/
Abstract

INTRODUCTION

The importance of immune tumor microenvironment in the prognosis of patients with head and neck squamous carcinomas (HNSCC) is increasingly recognized. We analyzed the prognostic relevance of PD-L1 and PD-1 expressions in relation to the infiltration by CD8 and FOXP3 tumor-infiltrating lymphocytes (TILs).

METHODS

Samples from 372 surgically treated HPV-negative HNSCC patients were evaluated by immunohistochemistry for PD-L1 expression [both tumor proportion score (TPS) and combined proportion score (CPS)], PD-1 expression in immune cells, and density of infiltrating CD8 and FOXP3 TILs. PD-L1 expression and CD8 TIL density were combined to establish the type of tumor microenvironment.

RESULTS

29.5% cases exhibited PD-L1 TPS positivity (≥ 1%), whereas PD-L1 CPS positivity (≥ 1%) was observed in 40% cases. 47.5% cases showed positive PD-1 expression (≥ 1%). PD-L1 and PD-1 positivity correlated with a high density of both CD8 and FOXP3 TILs. In univariate analysis, PD-L1 TPS positivity (P = 0.026), PD-L1 CPS positivity (P = 0.004), high density of CD8 TIL (P = 0.001), and high density of FOXP3 TIL (P = 0.004) were associated with a better disease-specific survival (DSS). However, in multivariate analysis, only high density of CD8 TIL was associated with a better DSS (P = 0.002). The type of tumor microenvironment correlated with DSS (P = .008), with the better DSS observed in cases with type I (PD-L1 CPS positivity and high density of CD8 TIL).

CONCLUSIONS

High infiltration by CD8 TIL is associated with better survival outcomes. Positive PD-L1 expression correlates with a high infiltration by TILs, explaining its association with better prognosis.

摘要

简介

免疫肿瘤微环境对头颈部鳞状细胞癌(HNSCC)患者的预后具有重要意义。我们分析了 PD-L1 和 PD-1 表达与 CD8 和 FOXP3 肿瘤浸润淋巴细胞(TIL)浸润的相关性及其预后意义。

方法

采用免疫组织化学方法检测 372 例手术治疗的 HPV 阴性 HNSCC 患者的 PD-L1 表达(肿瘤比例评分[TPS]和联合比例评分[CPS])、免疫细胞中的 PD-1 表达以及浸润性 CD8 和 FOXP3 TIL 的密度。将 PD-L1 表达和 CD8 TIL 密度结合起来建立肿瘤微环境的类型。

结果

29.5%的病例表现出 PD-L1 TPS 阳性(≥1%),而 40%的病例 PD-L1 CPS 阳性(≥1%)。47.5%的病例表现出 PD-1 阳性表达(≥1%)。PD-L1 和 PD-1 的阳性与 CD8 和 FOXP3 TIL 的高密度均相关。单因素分析显示,PD-L1 TPS 阳性(P=0.026)、PD-L1 CPS 阳性(P=0.004)、CD8 TIL 高密度(P=0.001)和 FOXP3 TIL 高密度(P=0.004)与疾病特异性生存(DSS)相关。然而,多因素分析显示,只有 CD8 TIL 高密度与更好的 DSS 相关(P=0.002)。肿瘤微环境的类型与 DSS 相关(P=0.008),其中 PD-L1 CPS 阳性和 CD8 TIL 高密度的病例 DSS 更好。

结论

CD8 TIL 的高浸润与生存结局改善相关。阳性 PD-L1 表达与 TIL 浸润相关,解释了其与更好预后的相关性。

相似文献

1
PD-L1 expression correlates with tumor-infiltrating lymphocytes and better prognosis in patients with HPV-negative head and neck squamous cell carcinomas.PD-L1 表达与 HPV 阴性头颈部鳞状细胞癌患者的肿瘤浸润淋巴细胞及预后相关。
Cancer Immunol Immunother. 2020 Oct;69(10):2089-2100. doi: 10.1007/s00262-020-02604-w. Epub 2020 May 24.
2
Characterization of the tumor immune microenvironment in human papillomavirus-positive and -negative head and neck squamous cell carcinomas.人乳头瘤病毒阳性和阴性头颈部鳞状细胞癌的肿瘤免疫微环境特征。
Cancer Immunol Immunother. 2021 May;70(5):1227-1237. doi: 10.1007/s00262-020-02747-w. Epub 2020 Oct 30.
3
Correlation of immune makers with HPV 16 infections and the prognosis in oropharyngeal squamous cell carcinoma.免疫标志物与 HPV16 感染及口咽鳞状细胞癌预后的相关性。
Clin Oral Investig. 2023 Apr;27(4):1423-1433. doi: 10.1007/s00784-023-04926-2. Epub 2023 Mar 8.
4
Tumor-infiltrating B cells affect the progression of oropharyngeal squamous cell carcinoma via cell-to-cell interactions with CD8 T cells.肿瘤浸润 B 细胞通过与 CD8 T 细胞的细胞间相互作用影响口咽鳞状细胞癌的进展。
J Immunother Cancer. 2019 Oct 17;7(1):261. doi: 10.1186/s40425-019-0726-6.
5
Prognostic and clinicopathological significance of PD-L1 and tumor infiltrating lymphocytes in hypopharyngeal squamous cell carcinoma.PD-L1 和肿瘤浸润淋巴细胞在下咽鳞状细胞癌中的预后及临床病理意义。
Oral Oncol. 2020 Mar;102:104560. doi: 10.1016/j.oraloncology.2019.104560. Epub 2020 Jan 7.
6
HPV-positive status associated with inflamed immune microenvironment and improved response to anti-PD-1 therapy in head and neck squamous cell carcinoma.HPV 阳性状态与头颈部鳞状细胞癌中炎症性免疫微环境相关,并改善了对抗 PD-1 治疗的反应。
Sci Rep. 2019 Sep 16;9(1):13404. doi: 10.1038/s41598-019-49771-0.
7
The prognostic role of PD-L1 expression for survival in head and neck squamous cell carcinoma: A systematic review and meta-analysis.PD-L1 表达对头颈鳞状细胞癌生存预后的预测作用:系统评价和荟萃分析。
Oral Oncol. 2018 Nov;86:81-90. doi: 10.1016/j.oraloncology.2018.09.016. Epub 2018 Sep 17.
8
Expression of immune response biomarkers (PD‑L1, p16, CD3+ and CD8+ TILs) in recurrent head and neck squamous cell carcinoma within previously irradiated areas.免疫反应生物标志物(PD-L1、p16、CD3+和 CD8+TILs)在既往照射区域内复发性头颈部鳞状细胞癌中的表达。
Oncol Rep. 2021 Mar;45(3):1273-1283. doi: 10.3892/or.2021.7928. Epub 2021 Jan 7.
9
PD-L1 Expression and a High Tumor Infiltrate of CD8+ Lymphocytes Predict Outcome in Patients with Oropharyngeal Squamous Cells Carcinoma.PD-L1 表达和 CD8+ 淋巴细胞的高肿瘤浸润可预测口咽鳞状细胞癌患者的结局。
Int J Mol Sci. 2020 Jul 23;21(15):5228. doi: 10.3390/ijms21155228.
10
Characteristics and impact of programmed death-ligand 1 expression, CD8+ tumor-infiltrating lymphocytes, and p16 status in head and neck squamous cell carcinoma.头颈部鳞状细胞癌中程序性死亡配体 1 表达、CD8+肿瘤浸润淋巴细胞和 p16 状态的特征和影响。
Med Oncol. 2019 Jan 21;36(2):21. doi: 10.1007/s12032-018-1241-1.

引用本文的文献

1
Molecular markers for the efficacy of neoadjuvant immunotherapy for head and neck squamous cell carcinoma.头颈部鳞状细胞癌新辅助免疫治疗疗效的分子标志物
Front Oncol. 2025 Jun 23;15:1586130. doi: 10.3389/fonc.2025.1586130. eCollection 2025.
2
The Role of Monoclonal Antibodies as Therapeutics in HPV-Related Head and Neck Cancers: An Updated Review.单克隆抗体作为治疗药物在人乳头瘤病毒相关头颈癌中的作用:最新综述
Antibodies (Basel). 2025 Apr 24;14(2):37. doi: 10.3390/antib14020037.
3
Mapping immunotherapy potential: spatial transcriptomics in the unraveling of tumor-immune microenvironments in head and neck squamous cell carcinoma.绘制免疫治疗潜力:空间转录组学在揭示头颈部鳞状细胞癌肿瘤免疫微环境中的应用
Front Immunol. 2025 Apr 8;16:1568590. doi: 10.3389/fimmu.2025.1568590. eCollection 2025.
4
The impact of histopathology on prognosis of squamous cell carcinoma of the larynx: can we do better?组织病理学对喉鳞状细胞癌预后的影响:我们能否做得更好?
Virchows Arch. 2025 Mar 27. doi: 10.1007/s00428-025-04082-w.
5
New insights on anti-tumor immunity of CD8 T cells: cancer stem cells, tumor immune microenvironment and immunotherapy.CD8 T细胞抗肿瘤免疫的新见解:癌症干细胞、肿瘤免疫微环境与免疫治疗
J Transl Med. 2025 Mar 17;23(1):341. doi: 10.1186/s12967-025-06291-y.
6
Frequent PD-L1 expression in oral squamous cell carcinoma of non-smokers and non-drinkers, and association of tumor infiltrating lymphocytes with favorable prognosis.非吸烟和非饮酒者口腔鳞状细胞癌中PD-L1的频繁表达以及肿瘤浸润淋巴细胞与良好预后的关联。
Transl Oncol. 2025 May;55:102357. doi: 10.1016/j.tranon.2025.102357. Epub 2025 Mar 15.
7
Stratification of the immunotypes of tongue squamous cell carcinoma to improve prognosis and the response to immune checkpoint inhibitors.对舌鳞状细胞癌免疫类型进行分层以改善预后及对免疫检查点抑制剂的反应。
Cancer Immunol Immunother. 2025 Mar 1;74(4):130. doi: 10.1007/s00262-025-03982-9.
8
CMTM6 status predicts survival in head and neck squamous cell carcinoma and correlates with PD-L1 expression.CMTM6状态可预测头颈部鳞状细胞癌的生存率,并与PD-L1表达相关。
Discov Oncol. 2024 Dec 4;15(1):745. doi: 10.1007/s12672-024-01554-4.
9
Expression of PD-L1, PD-L2, and inflammatory gene expression profile in locally advanced head and neck squamous cell carcinoma.局部晚期头颈部鳞状细胞癌中PD-L1、PD-L2的表达及炎症基因表达谱
ESMO Open. 2024 Nov;9(11):103961. doi: 10.1016/j.esmoop.2024.103961. Epub 2024 Oct 25.
10
MHC-I and PD-L1 Expression is Associated with Decreased Tumor Outgrowth and is Radiotherapy-inducible in the Murine Head and Neck Squamous Cell Carcinoma Model MOC1.MHC-I 和 PD-L1 的表达与肿瘤生长减少有关,并可在鼠头颈部鳞状细胞癌模型 MOC1 中诱导放疗。
Mol Imaging Biol. 2024 Oct;26(5):835-846. doi: 10.1007/s11307-024-01934-w. Epub 2024 Jul 15.

本文引用的文献

1
Prognostic and clinicopathological significance of PD-L1 and tumor infiltrating lymphocytes in hypopharyngeal squamous cell carcinoma.PD-L1 和肿瘤浸润淋巴细胞在下咽鳞状细胞癌中的预后及临床病理意义。
Oral Oncol. 2020 Mar;102:104560. doi: 10.1016/j.oraloncology.2019.104560. Epub 2020 Jan 7.
2
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC).癌症免疫治疗学会关于免疫治疗头颈部鳞状细胞癌(HNSCC)的共识声明。
J Immunother Cancer. 2019 Jul 15;7(1):184. doi: 10.1186/s40425-019-0662-5.
3
The prognostic role of PD-L1 expression for survival in head and neck squamous cell carcinoma: A systematic review and meta-analysis.PD-L1 表达对头颈鳞状细胞癌生存预后的预测作用:系统评价和荟萃分析。
Oral Oncol. 2018 Nov;86:81-90. doi: 10.1016/j.oraloncology.2018.09.016. Epub 2018 Sep 17.
4
Prognostic significance of tumor-infiltrating lymphocytes in patients with operable tongue cancer.肿瘤浸润淋巴细胞对可手术治疗的舌癌患者的预后意义。
Radiat Oncol. 2018 Aug 28;13(1):157. doi: 10.1186/s13014-018-1099-6.
5
Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012.帕博利珠单抗治疗复发性/转移性头颈部鳞状细胞癌的疗效和安全性:KEYNOTE-012 长期随访后的汇总分析。
Br J Cancer. 2018 Jul;119(2):153-159. doi: 10.1038/s41416-018-0131-9. Epub 2018 Jun 29.
6
Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression.纳武利尤单抗对比研究者选择的方案治疗复发性或转移性头颈部鳞状细胞癌:CheckMate 141 研究 2 年长期生存随访结果更新,且根据肿瘤 PD-L1 表达进行分析。
Oral Oncol. 2018 Jun;81:45-51. doi: 10.1016/j.oraloncology.2018.04.008. Epub 2018 Apr 17.
7
PD-1 and PD-L1 expression in HNSCC primary cancer and related lymph node metastasis - impact on clinical outcome.PD-1 和 PD-L1 在头颈部鳞癌原发灶及相关淋巴结转移中的表达及其对临床结局的影响。
Histopathology. 2018 Oct;73(4):573-584. doi: 10.1111/his.13646. Epub 2018 Jul 4.
8
Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations.PD-1 和 PD-L1 抑制剂作为癌症免疫疗法的一种形式的发展:注册试验的综合回顾和未来的考虑。
J Immunother Cancer. 2018 Jan 23;6(1):8. doi: 10.1186/s40425-018-0316-z.
9
Association between PD-L1 expression combined with tumor-infiltrating lymphocytes and the prognosis of patients with advanced hypopharyngeal squamous cell carcinoma.程序性死亡配体1(PD-L1)表达联合肿瘤浸润淋巴细胞与晚期下咽鳞状细胞癌患者预后的相关性
Oncotarget. 2017 Oct 6;8(54):92699-92714. doi: 10.18632/oncotarget.21564. eCollection 2017 Nov 3.
10
The prognostic role of tumor infiltrating T-lymphocytes in squamous cell carcinoma of the head and neck: A systematic review and meta-analysis.肿瘤浸润性T淋巴细胞在头颈部鳞状细胞癌中的预后作用:一项系统评价和荟萃分析。
Oncoimmunology. 2017 Aug 9;6(11):e1356148. doi: 10.1080/2162402X.2017.1356148. eCollection 2017.